- In September 2022, Polyplus, a prominent provider of upstream solutions for biologic and cell and gene therapy, expanded its mRNA support portfolio. The launch of in vivo-jetRNA+ transfection reagent enhances in vivo mRNA delivery with a preformed liposome. This addition signifies Polyplus' commitment to advancing efficient and precise transfection methods in the field of gene therapy
- In February 2022, Mirus Bio, a key player in delivery solutions under Gamma Biosciences, launched the TransIT-VirusGEN SELECT Transfection Kits. Specifically designed for large-scale viral vector production, these kits cater to the demands of cell and gene therapy applications, showcasing Mirus Bio's commitment to advancing efficient and scalable transfection solutions in the biotechnology industry
- In August 2021, Mirus Bio, a prominent player in transfection technologies, launched viral vector transfection kits tailored for cell and gene therapy manufacturing. These specialized transfection reagents aim to optimize the delivery of packaging and transfer vector DNA to suspension, enhancing the production of recombinant adeno-associated virus AAV) and lentivirus LV) vectors
- In November 2020, Thermo Fisher Scientific Inc. partnered with Northeastern University, enhancing innovation in the biopharmaceutical industry, particularly in gene and cell therapies. By consistently developing advanced reagents and techniques, the collaboration aimed to bolster sensitivity and accuracy in experiments and drug development, contributing to the production of valuable and efficient tools crucial for the transfection process
Frequently Asked Questions
The market is segmented based on , By Type Transient Transfection, Stable Transfection), Methods Non-Viral Methods, Viral Methods), CRISPR Transfection Methods Non-Viral Methods, Viral Methods), Products Reagent & Kits, Instrument, Software), Organism Mammalian Cells, Plants, Fungi, Virus, Bacteria), Types of Molecule Plasmid DNA, Small Interfering RNA siRNA), Proteins, DNA Oligonucleotides, Ribonucleoprotein Complexes RNPs), Others), Application In Vitro Application, In Vivo Application, Bioproduction, Others), Stage Research, Preclinical, Clinical Phases, Commercial), End User Biopharma, Contract Research Organizations CROs), Contract Manufacturing Organization/ Contract Development and Manufacturing Organization CMOs/CDMOs), Academia, Hospitals, Clinical Labs, Others), Distribution Channel Direct Tender, Retail Sales, Others) – Industry Trends and Forecast to 2032
.
The Global Transfection Market size was valued at USD 1.30 USD Billion in 2024.
The Global Transfection Market is projected to grow at a CAGR of 9.64% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa , Brazil, Argentina and Rest of South America.
